Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WGc-0901
- Development stage
- Preclinical
- Lead developer
- Chengdu Weisijin Biopharmaceutical Technology
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
WGc-0901 is a preclinical mRNA-based tumor vaccine candidate developed by WestGene for the treatment of solid tumors. As part of WestGene's tumor treatment vaccine platform, the drug utilizes mRNA technology to induce anti-tumor immune responses. While the specific antigen targets have not been disclosed, the vaccine is intended to stimulate the immune system to recognize and eliminate malignant cells in various solid tumor types.
Beyond the preview
Go deeper on WGc-0901.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WGc-0901.